Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis
siRNA therapies demonstrate significant efficacy in reducing triglycerides and improving lipid profiles in patients with HTG and mixed dyslipidemia. APOC3-targeted treatments primarily reduce triglycerides while increasing HDL-C, whereas ANGPTL3-targeted therapies offer broader lipid modulation, including substantial reductions in LDL-C. Both therapies demonstrate favorable safety profiles.
Authors
- Xingxue Pang (ORCID: https://orcid.org/0000-0002-2878-9846)
- Yifan Gao (ORCID: https://orcid.org/0000-0002-9184-0085)
- Xu Mu
- Yanmin Bai
Institutions
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.3389/fphar.2026.1736821
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00